vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and PROSPERITY BANCSHARES INC (PB). Click either name above to swap in a different company.
PROSPERITY BANCSHARES INC is the larger business by last-quarter revenue ($367.6M vs $196.0M, roughly 1.9× Axsome Therapeutics, Inc.). PROSPERITY BANCSHARES INC runs the higher net margin — 31.6% vs -14.6%, a 46.2% gap on every dollar of revenue. Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 19.2%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Prosperity Bancshares, Inc. is a bank holding company headquartered in Houston, Texas with operations in Texas and central Oklahoma. As of December 31, 2019, the company operated 285 branches: 65 in the Houston area, including The Woodlands, Texas; 30 in South Texas, including Corpus Christi, Texas and Victoria, Texas; 75 in the Dallas–Fort Worth metroplex; 22 in East Texas; 29 in Central Texas, including Austin, Texas and San Antonio; 34 in West Texas, including Lubbock, Texas, Midland–Odess...
AXSM vs PB — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $367.6M |
| Net Profit | $-28.6M | $116.3M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | — |
| Net Margin | -14.6% | 31.6% |
| Revenue YoY | 65.0% | — |
| Net Profit YoY | 61.9% | -10.7% |
| EPS (diluted) | $-0.55 | $1.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $367.6M | ||
| Q4 25 | $196.0M | $275.0M | ||
| Q3 25 | $171.0M | $273.4M | ||
| Q2 25 | $150.0M | $267.7M | ||
| Q1 25 | $121.5M | $265.4M | ||
| Q4 24 | $118.8M | $267.8M | ||
| Q3 24 | $104.8M | $261.7M | ||
| Q2 24 | $87.2M | $258.8M |
| Q1 26 | — | $116.3M | ||
| Q4 25 | $-28.6M | $139.9M | ||
| Q3 25 | $-47.2M | $137.6M | ||
| Q2 25 | $-48.0M | $135.2M | ||
| Q1 25 | $-59.4M | $130.2M | ||
| Q4 24 | $-74.9M | $130.1M | ||
| Q3 24 | $-64.6M | $127.3M | ||
| Q2 24 | $-79.3M | $111.6M |
| Q1 26 | — | — | ||
| Q4 25 | -13.8% | 65.1% | ||
| Q3 25 | -27.0% | 64.4% | ||
| Q2 25 | -24.5% | 64.3% | ||
| Q1 25 | -46.9% | 62.7% | ||
| Q4 24 | -61.1% | 62.0% | ||
| Q3 24 | -59.8% | 62.1% | ||
| Q2 24 | -89.5% | 55.2% |
| Q1 26 | — | 31.6% | ||
| Q4 25 | -14.6% | 50.9% | ||
| Q3 25 | -27.6% | 50.3% | ||
| Q2 25 | -32.0% | 50.5% | ||
| Q1 25 | -48.9% | 49.1% | ||
| Q4 24 | -63.1% | 48.6% | ||
| Q3 24 | -61.7% | 48.6% | ||
| Q2 24 | -91.0% | 43.1% |
| Q1 26 | — | $1.16 | ||
| Q4 25 | $-0.55 | $1.48 | ||
| Q3 25 | $-0.94 | $1.45 | ||
| Q2 25 | $-0.97 | $1.42 | ||
| Q1 25 | $-1.22 | $1.37 | ||
| Q4 24 | $-1.54 | $1.36 | ||
| Q3 24 | $-1.34 | $1.34 | ||
| Q2 24 | $-1.67 | $1.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $8.2B |
| Total Assets | $689.8M | $43.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $322.9M | — | ||
| Q3 25 | $325.3M | — | ||
| Q2 25 | $303.0M | — | ||
| Q1 25 | $300.9M | — | ||
| Q4 24 | $315.4M | — | ||
| Q3 24 | $327.3M | — | ||
| Q2 24 | $315.7M | — |
| Q1 26 | — | $8.2B | ||
| Q4 25 | $88.3M | $7.6B | ||
| Q3 25 | $73.7M | $7.7B | ||
| Q2 25 | $73.1M | $7.6B | ||
| Q1 25 | $53.2M | $7.5B | ||
| Q4 24 | $57.0M | $7.4B | ||
| Q3 24 | $92.9M | $7.4B | ||
| Q2 24 | $102.9M | $7.3B |
| Q1 26 | — | $43.6B | ||
| Q4 25 | $689.8M | $38.5B | ||
| Q3 25 | $669.3M | $38.3B | ||
| Q2 25 | $639.8M | $38.4B | ||
| Q1 25 | $596.7M | $38.8B | ||
| Q4 24 | $568.5M | $39.6B | ||
| Q3 24 | $561.5M | $40.1B | ||
| Q2 24 | $548.2M | $39.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | — |
| Free Cash FlowOCF − Capex | $-18.7M | — |
| FCF MarginFCF / Revenue | -9.6% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $78.3M | ||
| Q3 25 | $1.0M | $194.8M | ||
| Q2 25 | $-32.4M | $98.2M | ||
| Q1 25 | $-43.4M | $178.2M | ||
| Q4 24 | $-26.2M | $-205.8M | ||
| Q3 24 | $-18.6M | $274.6M | ||
| Q2 24 | $-30.1M | $216.5M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $68.5M | ||
| Q3 25 | $988.0K | $185.7M | ||
| Q2 25 | $-32.4M | $91.8M | ||
| Q1 25 | $-43.7M | $171.1M | ||
| Q4 24 | $-26.2M | $-210.7M | ||
| Q3 24 | $-18.7M | $270.2M | ||
| Q2 24 | $-30.2M | $211.8M |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | 24.9% | ||
| Q3 25 | 0.6% | 67.9% | ||
| Q2 25 | -21.6% | 34.3% | ||
| Q1 25 | -36.0% | 64.5% | ||
| Q4 24 | -22.1% | -78.7% | ||
| Q3 24 | -17.9% | 103.3% | ||
| Q2 24 | -34.6% | 81.8% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 3.6% | ||
| Q3 25 | 0.0% | 3.3% | ||
| Q2 25 | 0.0% | 2.4% | ||
| Q1 25 | 0.3% | 2.7% | ||
| Q4 24 | 0.0% | 1.8% | ||
| Q3 24 | 0.1% | 1.7% | ||
| Q2 24 | 0.1% | 1.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.56× | ||
| Q3 25 | — | 1.42× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 1.37× | ||
| Q4 24 | — | -1.58× | ||
| Q3 24 | — | 2.16× | ||
| Q2 24 | — | 1.94× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
PB
| Net Interest Income | $321.1M | 87% |
| Noninterest Income | $46.5M | 13% |
